Overview of Ixor (Roxithromycin)

Property	Description
Active ingredient	Roxithromycin
Form	Film-coated tablet (Oral preparation)
Pharmacological class	Macrolide Antibiotic
Common use	Systemic antibacterial chemotherapy
Origin	Semisynthetic

What is Roxithromycin (Ixor) and Its Pharmacological Identity?

Ixor is a medicinal preparation containing the active ingredient Roxithromycin, which is classified as a semisynthetic macrolide antibiotic and acts as an antimicrobial agent for systemic use. Roxithromycin belongs to the Macrolide class, a group of antibiotics defined by their distinctive chemical structure, a large macrocyclic lactone ring. This substance is clinically recognized for its systemic delivery in combating infections. As a modification of Erythromycin, Roxithromycin is designed for improved stability, a differentiating factor in its profile, and is strictly designated for professional dispensing as a prescription-only product.

Composition, Origin, and Available Pharmaceutical Form

The compound Roxithromycin is chemically identified as a semisynthetic derivative of Erythromycin A. This means the active substance is created by chemically altering a natural precursor to optimize its therapeutic properties. The product is consistently supplied as a single active ingredient preparation, typically presented as an oral preparation in the form of a film-coated tablet. This tablet form is essential for systemic administration, ensuring the precise delivery of the Roxithromycin entity. The use of a film coating is a distinctive feature of this preparation, aiding in drug stability until absorption.

General Purpose and Mechanism of Action Overview

The general purpose of Roxithromycin is to provide systemic antibacterial chemotherapy to help resolve infections caused by susceptible organisms. Its efficacy stems from its function as a protein synthesis inhibitor; it specifically targets the 50S ribosomal subunit within the bacterial cell, thereby halting the formation of proteins essential for growth. This action characterizes the drug as a bacteriostatic agent, which is important because it suppresses the proliferation of bacteria, providing the body's immune system with the necessary advantage to clear the infection.

Regulatory References

Macrolides - StatPearls - NCBI Bookshelf

What side effects are possible with Ixor (Roxithromycin)?

Possible Side Effects and Safety Information

The safety profile of Roxithromycin, a macrolide antibiotic, is defined by officially documented adverse reactions categorized by their frequency and the system-organ class involved, as detailed in regulatory labeling.

Commonly Documented Adverse Reactions

Adverse effects listed as Common (occurring in ge 1/100 to < 1/10 of patients) typically involve the Gastrointestinal System and the Nervous System. These frequently include Nausea, Vomiting, Diarrhoea, Abdominal Pain, Headache, and Dizziness. Gastrointestinal disturbances are often reported as being more likely to occur at the start of treatment.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several rare but clinically significant adverse reactions, categorized as Rare or Very Rare. These serious reactions include severe Cardiac Arrhythmias, specifically QT interval prolongation leading to Torsades de pointes. Other serious effects are severe Hepatotoxicity (e.g., Jaundice and Hepatitis), Pancreatitis, and severe hypersensitivity reactions such as Stevens-Johnson syndrome (SJS) and Anaphylaxis.

Population-Specific Safety Notes

Roxithromycin is explicitly Contraindicated in individuals with a known allergy to any macrolide antibiotic. Furthermore, use is generally contraindicated in patients with severe hepatic impairment. Caution is advised in patients with existing cardiac conditions or those taking specific medications that also prolong the QT interval, as this increases the risk of serious cardiac events. The regulatory profile notes that prolonged treatment may necessitate monitoring of liver function and blood counts.

Overdose and Emergency Response

If you suspect that you or someone else has taken more Ixor (Roxithromycin) than prescribed, it is crucial to seek immediate medical attention. While no specific antidote exists for Roxithromycin overdose, prompt professional care can manage symptoms and provide supportive treatment.

Symptoms of Overdose

Symptoms of a Roxithromycin overdose are typically centered on the gastrointestinal system, though other effects may occur. Commonly reported signs include:

Nausea and Vomiting
Diarrhea
Abdominal pain

Less frequently, other signs such as headache or dizziness have been reported. A very large overdose of any macrolide antibiotic can theoretically pose a risk of serious cardiac effects, such as prolongation of the QT interval, which can lead to irregular heart rhythms. This is why immediate medical evaluation is essential.

When to Seek Help

Always contact emergency medical services or a poison control center immediately if an overdose is suspected, even if the person appears well. Bring the medication package or label with you to the hospital. Treatment typically involves managing symptoms, supportive measures, and may include activated charcoal or gastric lavage in certain situations, depending on the amount taken and the time elapsed since ingestion. Do not induce vomiting unless specifically advised to do so by a healthcare professional.

Therapeutic Uses of Ixor (Roxithromycin)

What Ixor (Roxithromycin) Treats: Main Uses and Benefits

Roxithromycin, classified as a macrolide antibiotic, is primarily used for systemic antibacterial chemotherapy in acute or episodic bacterial infections where the causative organisms may be susceptible to this class. It is applied across several key therapeutic domains and may assist in managing the overall symptomatic burden.

The medication is generally applicable for conditions presenting with acute episodes, such as respiratory tract infections (RTIs) like tonsillitis and bronchitis, skin and soft tissue infections (SSTIs) including cellulitis, and specific non-gonococcal urogenital infections. Its use is relevant for easing symptoms related to inflammatory or irritative states, like fever, cough, and localized pain.

It is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

“This application provides symptomatic relief and supports functional stability during acute phases.”

Quick Fact: Relief for Inflammatory Discomfort

The use of Roxithromycin is applied when appropriate when additional symptomatic support is needed to address clusters of symptoms related to localized inflammation and systemic imbalance caused by susceptible bacteria. This supports functional stability and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

Official New Zealand Medsafe Datasheet

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Roxithromycin

The eligibility profile for Roxithromycin (Ixor) is strictly defined by regulatory authorities based on specific clinical and physiological factors, establishing clear criteria for use and contraindications.

Contraindications (Must Not Use)	Use Restrictions (Conditional or Not Recommended)
Macrolide Hypersensitivity: Allergy to roxithromycin or any macrolide antibiotic.	Severe Hepatic Impairment: Not recommended. If use is essential, the dose must be reduced by half.
Cardiac Risk: History of congenital or acquired Long QT Syndrome or concurrent use of certain QT-prolonging agents (e.g., cisapride, terfenadine).	Pregnancy/Lactation: Use is generally not recommended during pregnancy unless clearly indicated; there is no clinical experience on use during lactation.
Ergot Alkaloids: Concomitant use with vasoconstrictive ergot alkaloids is prohibited.	Children under 40 kg: Use is generally not recommended, and the tablet form is not suitable for children under 6 years of age.

Standard Eligibility: The medicine is generally permitted for use in adults and older adults, though particular caution is advised for older patients with proarrhythmic conditions. It is also cleared for use in patients with impaired renal function without mandatory dose adjustment, indicating eligibility for standard use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities define specific restrictions and requirements for co-administering Roxithromycin with other medicines and substances.

Mandatory Restrictions

Co-administration is strictly contraindicated with vasoconstrictive ergot alkaloids, such as Ergotamine and Dihydroergotamine, due to the officially documented risk of severe vasoconstriction (ergotism). Additionally, some regulatory bodies classify the combination with Astemizole and Terfenadine as contraindicated due to the risk of additive QT interval prolongation and serious cardiac events.

Exposure Alterations

Roxithromycin may officially alter the plasma concentration of co-administered drugs. Regulatory labels document an increase in the plasma concentration of Theophylline and Ciclosporin (Cyclosporin A). Similarly, the official profile notes that co-administration can enhance and prolong the effect of Midazolam and lead to increased serum levels of unbound Disopyramide due to protein-binding displacement. Roxithromycin can also increase the absorption of Digoxin and other cardiac glycosides.

Pharmacodynamic and Other Constraints

A significant interaction is noted with Vitamin K Antagonists (e.g., Warfarin), where reports indicate an increased International Normalized Ratio (INR), reflecting an enhanced anticoagulant effect. Concomitant use with Class IA and Class III Antiarrhythmic Agents is constrained by the risk of additive QT interval prolongation. Furthermore, regulatory information states that taking the oral preparation with food results in decreased absorption of Roxithromycin. A population-specific consideration exists for patients with impaired hepatic function, as the Roxithromycin half-life is officially increased, heightening the risk for exposure-related interactions.

Mechanism of Action

How Ixor (Roxithromycin) Works

Molecular Inhibition of Bacterial Growth

Roxithromycin exerts its primary effect by binding non-covalently to the bacterial 50S ribosomal subunit . This binding physically blocks the exit tunnel for the nascent polypeptide chain, thereby inhibiting the essential translocation step required for the elongation of proteins. This mechanism arrests the growth and multiplication of susceptible bacteria, resulting in a bacteriostatic effect that suppresses microbial proliferation.

️ Non-Antibiotic Modulation of Immune Response

Beyond its direct antimicrobial action, the drug engages secondary mechanisms by modulating inflammatory signaling pathways within host immune cells. Roxithromycin can downregulate transcription factors (like NF-κB) responsible for initiating the production of pro-inflammatory mediators (e.g., IL-8). This action contributes to the downregulation of inflammatory responses, which limits the signaling of pro-inflammatory mediators at the site of microbial activity.

Targeted Intracellular Drug Delivery

A key mechanistic factor is the drug's ability to accumulate inside phagocytic immune cells (e.g., macrophages and neutrophils) . These drug-loaded cells facilitate the active transport of the molecule, allowing high concentrations to be delivered to deep tissue compartments. This targeted accumulation allows the drug to concentrate in areas of cellular pathology, which is relevant for its action against intracellular pathogens.

Dosage and Administration Information

How to Use Ixor (Roxithromycin) — Administration Guidelines

This section outlines the administration instructions for Roxithromycin. It provides neutral, non-advisory information regarding its standard use.

Administration Details

Feature	Instruction
Route of Administration	Oral (by mouth).
Timing Relative to Meals	Must be taken on an empty stomach. This is typically defined as at least 15 minutes before a meal or more than 3 hours after a meal.
Method of Intake	Tablets should be swallowed whole with a glass of water. Do not crush or chew unless using a dispersible tablet formulation.
Frequency	Once daily (OD) or twice daily (BD). Must be taken at approximately the same time(s) each day.

Dosage and Duration

Standard Adult Dosing

The standard daily dose is 300 mg. This may be achieved through one of the following regimens:

One 300 mg tablet taken once daily.
One 150 mg tablet taken twice daily.

Population-Specific Adjustments

Severe Hepatic Impairment: The daily dose is reduced by half to 150 mg once daily for patients with severe liver insufficiency.
Renal Impairment/Elderly: No dosage adjustment is typically required.

Course Duration

Treatment duration is usually 5 to 10 days, depending on the specific infection. For certain infections, such as those caused by Streptococcus, a minimum course of 10 days is required to ensure eradication.

Disclaimer: This information is not a substitute for professional medical guidance. Always follow the specific instructions provided by your healthcare professional and the patient information leaflet.

Recent Clinical Evidence

Research evidence / Overview of studies for Ixor (Roxithromycin)

Evidence for Acute Infections (RTIs and SSTIs)

Research has explored Roxithromycin in the context of conditions associated with acute or disruptive episodes, such as respiratory tract infections (RTIs) and skin and soft tissue infections (SSTIs). The evidence is largely derived from Randomized Controlled Trials (RCTs) where the drug was studied in parallel with other established antibiotics in adult populations. Studies monitored outcomes related to systemic or functional imbalance, including clinical response and bacteriological clearance. Studies report patterns of change in outcomes that were comparable to those observed with some comparison treatments. For SSTIs, studies explored pharmacokinetic parameters by monitoring drug levels in affected tissues. Research so far indicates that results may vary between studies, and the evidence quality varies across studies, with some systematic reviews noting that the evidence base for optimal duration in SSTIs remains insufficient.

Long-Term Research and Evidence Gaps

Beyond acute uses, specialized, long-term, placebo-controlled RCTs research examined temporary physiological imbalance in patients with specific long-term chronic conditions (e.g., bronchiectasis and asthma). This research was studied for non-antibacterial properties. However, long-term effects are not fully established for these specialized uses, and this area of investigation has an overall low certainty rating. For all indications, follow-up durations were limited to the short term (around 10–28 days). Research has not extensively established whether the measured short-term outcomes correlate with long-term functional status. Data for certain groups remain insufficient, especially for definitive clinical outcomes in children or specific high-risk patient populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ixor (Roxithromycin) (FAQ)

Q: Can taking Ixor cause stomach upset or diarrhea?

A: Yes, official regulatory information states that Ixor commonly causes side effects affecting the gastrointestinal system. These frequently include diarrhea, nausea, vomiting, and abdominal pain.

Q: Does Ixor affect birth control pills?

A: Official drug profiles indicate that roxithromycin does not appear to interact with oral contraceptives that contain oestrogens and progestogens. Patients should always consult with a healthcare professional regarding any medication concerns.

Q: Is there a generic version of Ixor available?

A: Yes, Ixor contains the active ingredient Roxithromycin. This substance is available globally under multiple generic brand names, although it is not approved for marketing in the United States.

Q: Does Ixor interact with common heartburn medications?

A: Official drug information suggests that roxithromycin does not typically interact with antacids or commonly used heartburn medications like ranitidine. It is important for patients to inform their healthcare providers about all medications being taken.

Q: What is the research evidence showing Ixor is effective for chest infections?

A: Official prescribing information confirms that Roxithromycin is indicated and studied for respiratory tract infections (RTIs). This includes conditions often referred to as chest infections, such as acute bronchitis and pneumonia.

Q: Can Ixor cause changes in my sense of taste or smell?

A: While not common, some post-market reports associated with macrolide antibiotics suggest potential side effects like taste and smell disorders (dysgeusia). Any changes to the sense of taste or smell should be reported to a healthcare professional.

Q: Can Ixor be taken while breastfeeding?

A: Regulatory information indicates that Roxithromycin passes into breast milk in small amounts. Official information advises cautious use during breastfeeding, and use should be monitored by a healthcare professional.

Q: Can pregnant women safely take Ixor?

A: Use during pregnancy is generally not recommended. Regulatory labeling indicates that use is only permitted when clearly necessary and after assessment by a healthcare provider.

Q: What kind of infections does Ixor actually treat?

A: Ixor is officially indicated for treating a range of infections caused by susceptible organisms. These typically include infections like acute pharyngitis, tonsillitis, sinusitis, acute bronchitis, pneumonia, and skin and soft tissue infections.

Q: Is Ixor a type of penicillin, or is it something different?

A: Ixor (Roxithromycin) is not a penicillin. It is chemically classified as a semisynthetic macrolide antibiotic, which belongs to a distinct class of antibacterial medicines.

Q: What happens if I miss a dose of Ixor by a few hours?

A: Official guidance on missed doses advises following a set protocol to avoid taking too much medicine. Patients should consult their patient information leaflet or healthcare professional for specific instructions on how to proceed.

Q: Can Ixor be taken with food, or does it have to be on an empty stomach?

A: Ixor must be taken on an empty stomach. Official regulatory information notes that taking the medicine with food results in decreased absorption, which could reduce the drug's effectiveness against the infection.

Q: How long does Ixor stay in your system after you stop taking it?

A: The time it takes for a drug to clear the body is related to its elimination half-life, which for roxithromycin is approximately 10 to 13 hours. It takes several half-lives for the drug to be fully eliminated.

Q: Can I stop taking Ixor as soon as my symptoms clear up?

A: No. Official guidance states that the full course must be completed as prescribed to ensure the eradication of the infection and minimize the risk of bacterial resistance.

Q: Does Ixor have an expiration date I should watch out for?

A: Yes. The packaging, such as the blister pack, will display the expiration date for the medicine. Ixor should not be used past this date and must be disposed of properly.

Q: Is it safe to drive after taking Ixor?

A: Official warnings advise caution when driving or operating machinery. This is because common side effects like dizziness or headache could potentially impair a person's ability to perform these tasks safely.

Q: Why do doctors prescribe Ixor for skin infections?

A: Ixor is indicated for skin and soft tissue infections due to its mechanism of action. The drug is known to accumulate inside immune cells (phagocytes), which helps deliver the antibacterial agent directly to the site of cellular pathology.

Q: Can Ixor be taken by children, and is the dosage different?

A: Yes, Ixor can be used in children, but the dosage is different and must be calculated based on the child's body weight. The tablet form is generally not suitable for very young children.

Q: What should I do if I vomit shortly after taking a dose of Ixor?

A: If a patient vomits shortly after administration, they should contact a healthcare professional for guidance on whether further dosing is required, as minimal drug may have been absorbed.

Q: How long does a course of Ixor typically last?

A: A course of Ixor typically lasts 5 to 10 days. The exact length is determined by the specific type and severity of the infection being treated, with some infections requiring a specific minimum duration.

Q: Is it possible to be allergic to Ixor even if I wasn't allergic to other antibiotics?

A: Yes. Official contraindications state that Ixor must not be used if there is a known allergy to roxithromycin or any macrolide antibiotic. An allergy is specific and can occur regardless of previous reactions to other classes of antibiotics.

Q: Can Ixor make an existing fungal infection worse?

A: Yes. The use of Ixor can disrupt the body's natural balance of flora and may be associated with Candida infection (candidiasis) as a side effect, which suggests a risk of fungal overgrowth.

Q: Is Ixor known to cause heart palpitations?

A: The drug is associated with rare but serious risks, including changes in heart rhythm like QT interval prolongation and cardiac arrhythmias. Any patient experiencing symptoms such as palpitations should seek guidance from a healthcare professional.

Q: Is Ixor an older or newer type of antibiotic?

A: Roxithromycin is a semisynthetic derivative of Erythromycin A and was patented in 1980. This makes it a later generation macrolide, developed after the original Erythromycin, with improved pharmacological properties.

Q: What precautions should be taken when storing Ixor?

A: The official guidance states that precautions include storing the tablets below 25°C (77°F), keeping them in their original packaging, and ensuring they are kept out of the sight and reach of children.

How should Ixor (Roxithromycin) be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Ixor (Roxithromycin) are defined by regulatory authorities to maintain drug stability and ensure environmental safety.

Storage Conditions

Requirement	Specifics
Temperature	Store below 25°C (77°F).
Protection	Keep away from heat, direct sunlight, and moisture.
Packaging	Keep tablets in the original blister pack until use.
Security	Store medicine out of the reach of children.

Disposal Instructions

Do not dispose of this medicine in household trash or pour it down a sink or toilet. Proper disposal is required to protect the environment. Return any unused or expired Roxithromycin to a pharmacy or designated collection point as instructed by local health regulations.

Ixor (Roxithromycin)